Overview
Overview
PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe m
- Category
- Healing
- Routes
- subcutaneous
Mechanism
PNC-27
Mechanism of action
Mechanism of action
PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence [1] . Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells [2] [6] . Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration [4] . No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.
Key research findings
- 01
PNC-27 is described in the literature as a synthetic 32-residue chimeric research peptide joining the HDM-2 (MDM2)-binding domain of p53 (residues 12-26) to a penetratin / membrane-residency 'leader' sequence; foundational design, NMR, and conformational studies report it adopts a p53-like HDM-2-binding helical structure (Kanovsky et al., PNAS 2001, PMID 11606716, doi:10.1073/pnas.211280698; Rosal et al., Biochemistry 2004, PMID 14967026, doi:10.1021/bi035718g; Sarafraz-Yazdi et al., Biomedicines 2022, PMID 35625682, doi:10.3390/biomedicines10050945).
- 02
In cultured cells, research reports PNC-27 co-localizes with HDM-2 present in the plasma membrane of cancer cell lines and is associated with transmembrane pore formation and necrosis (membranolysis), whereas untransformed cell lines reported to lack membrane HDM-2 were not affected; transfecting membrane-targeted HDM-2 into a resistant normal line reportedly conferred susceptibility (Sarafraz-Yazdi et al., PNAS 2010, PMID 20080680, doi:10.1073/pnas.0909364107; Sookraj et al., Cancer Chemother Pharmacol 2010, PMID 20182728, doi:10.1007/s00280-009-1166-7).
- 03
Selective cytotoxicity has been reported across multiple human cancer cell lines - including breast, pancreatic, ovarian, colon, and several leukemia lines (K562, U937, OCI-AML3, HL-60) - measured by LDH release and viability assays, with effects reported as independent of intracellular p53 status (Davitt et al., Ann Clin Lab Sci 2014, PMID 25117093; Thadi et al., Anticancer Res 2020, PMID 32878773, doi:10.21873/anticanres.14488; Thadi et al., Ann Clin Lab Sci 2020, PMID 33067207).
- 04
Beyond the plasma membrane, recent work reports PNC-27 also localizes to mitochondrial membranes of treated cancer cells and is associated with mitochondrial disruption (Krzesaj et al., Ann Clin Lab Sci 2024, PMID 38802154).
- 05
In rodent tumor models - an intraperitoneal ID8 ovarian model and human/murine acute myeloid leukemia transplant models - researchers reported reduced tumor burden after PNC-27 administration; notably, an independent group reported selective killing of AML cells including leukemia stem cells while sparing normal hematopoietic stem cells (Alagkiozidis et al., Ann Clin Lab Sci 2017, PMID 28667027; Wang et al., Leukemia 2019, PMID 31337857, doi:10.1038/s41375-019-0522-9).
- 06
In freshly isolated patient-derived epithelial ovarian cancer cells, dose-dependent cytotoxicity was reported in laboratory assays; this is ex vivo cell work and does not constitute a human clinical study (Sarafraz-Yazdi et al., Ann Clin Lab Sci 2015, PMID 26663795).
Primary source: PNC-27 has a genuine, indexed peer-reviewed evidence base spanning roughly 2001-2024 (20+ PubMed-indexed papers, including primary mechanism studies in PNAS, Biochemistry, and Leukemia), which is more developed than many research peptides; however, the work is entirely preclinical - in vitro cell-line and ex vivo patient-derived cell studies plus rodent tumor models - with no registered human clinical trials (confirmed via ClinicalTrials.gov). Most studies originate from a single affiliated research network (SUNY Downstate / Drexel / NomoCan), with limited independent replication, the main exception being an independent in vivo leukemia study, so conclusions remain preliminary.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 while sparing normal cells[2][6].
Mechanism involves direct membrane lysis rather than apoptosis in affected cells[7].
No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established[3].
Possible injection‑site reactions (redness, irritation) may occur with subcutaneous administration.
Protocol Reference
Protocol reference
Commonly cited research range: 100–500 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
100 mcg (0.10 mg)
Weeks 3–4
200 mcg (0.20 mg)
Weeks 5–8
300 mcg (0.30 mg)
Weeks 9–12
400 mcg (0.40 mg)
Weeks 13–16
500 mcg (0.50 mg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 1 unit (0.01 mL) |
| Weeks 3–4 | 200 mcg (0.20 mg) | 2 units (0.02 mL) |
| Weeks 5–8 | 300 mcg (0.30 mg) | 3 units (0.03 mL) |
| Weeks 9–12 | 400 mcg (0.40 mg) | 4 units (0.04 mL) |
| Weeks 13–16 | 500 mcg (0.50 mg) | 5 units (0.05 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; short‑term refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
In vitro and animal studies report selective cytotoxicity toward certain cancer cell lines; this is early preclinical research only.
PNC-27 has a genuine, indexed peer-reviewed evidence base spanning roughly 2001-2024 (20+ PubMed-indexed papers, including primary mechanism studies in PNAS, Biochemistry, and Leukemia), which is more developed than many research peptides; however, the work is entirely preclinical - in vitro cell-line and ex vivo patient-derived cell studies plus rodent tumor models - with no registered human clinical trials (confirmed via ClinicalTrials.gov). Most studies originate from a single affiliated research network (SUNY Downstate / Drexel / NomoCan), with limited independent replication, the main exception being an independent in vivo leukemia study, so conclusions remain preliminary.
- 01PNC-27 is described in the literature as a synthetic 32-residue chimeric research peptide joining the HDM-2 (MDM2)-binding domain of p53 (residues 12-26) to a penetratin / membrane-residency 'leader' sequence; foundational design, NMR, and conformational studies report it adopts a p53-like HDM-2-binding helical structure (Kanovsky et al., PNAS 2001, PMID 11606716, doi:10.1073/pnas.211280698; Rosal et al., Biochemistry 2004, PMID 14967026, doi:10.1021/bi035718g; Sarafraz-Yazdi et al., Biomedicines 2022, PMID 35625682, doi:10.3390/biomedicines10050945).
- 02In cultured cells, research reports PNC-27 co-localizes with HDM-2 present in the plasma membrane of cancer cell lines and is associated with transmembrane pore formation and necrosis (membranolysis), whereas untransformed cell lines reported to lack membrane HDM-2 were not affected; transfecting membrane-targeted HDM-2 into a resistant normal line reportedly conferred susceptibility (Sarafraz-Yazdi et al., PNAS 2010, PMID 20080680, doi:10.1073/pnas.0909364107; Sookraj et al., Cancer Chemother Pharmacol 2010, PMID 20182728, doi:10.1007/s00280-009-1166-7).
- 03Selective cytotoxicity has been reported across multiple human cancer cell lines - including breast, pancreatic, ovarian, colon, and several leukemia lines (K562, U937, OCI-AML3, HL-60) - measured by LDH release and viability assays, with effects reported as independent of intracellular p53 status (Davitt et al., Ann Clin Lab Sci 2014, PMID 25117093; Thadi et al., Anticancer Res 2020, PMID 32878773, doi:10.21873/anticanres.14488; Thadi et al., Ann Clin Lab Sci 2020, PMID 33067207).
- 04Beyond the plasma membrane, recent work reports PNC-27 also localizes to mitochondrial membranes of treated cancer cells and is associated with mitochondrial disruption (Krzesaj et al., Ann Clin Lab Sci 2024, PMID 38802154).
- 05In rodent tumor models - an intraperitoneal ID8 ovarian model and human/murine acute myeloid leukemia transplant models - researchers reported reduced tumor burden after PNC-27 administration; notably, an independent group reported selective killing of AML cells including leukemia stem cells while sparing normal hematopoietic stem cells (Alagkiozidis et al., Ann Clin Lab Sci 2017, PMID 28667027; Wang et al., Leukemia 2019, PMID 31337857, doi:10.1038/s41375-019-0522-9).
- 06In freshly isolated patient-derived epithelial ovarian cancer cells, dose-dependent cytotoxicity was reported in laboratory assays; this is ex vivo cell work and does not constitute a human clinical study (Sarafraz-Yazdi et al., Ann Clin Lab Sci 2015, PMID 26663795).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to PNC-27.
- 01Journal of Biomedical Science (2017) — Review of therapeutic peptides; PNC-27 mechanism and cancer cell selectivity View Sourceet al. (2017)
- 02Cancer Chemotherapy and Pharmacology (2010) — PNC-27 induces tumor cell membrane lysis; preclinical mechanism study View Sourceet al. (2010)
- 03FDA Drug Safety Communication (2015) — Warning: PNC-27 is unapproved; safety not established View Sourceet al. (2015)
- 04International Journal of Cancer (2006) — PNC-28 (related peptide) blocks pancreatic cancer growth in vivo; mouse model study View Sourceet al. (2006)
- 05Peptide Sciences — Peptide storage guidelines: lyophilized and reconstituted stability View Source
- 06BMC Cancer (2008) — PNC-27 selectively kills cancer cells via HDM-2 binding and membrane disruption View Sourceet al. (2008)
- 07PubMed (2012) — PNC-27 peptide induces necrosis via direct membrane lysis mechanism View Sourceet al. (2012)
- 08CDC — Vaccine administration: subcutaneous route (angle/site guidance) View Source
- 09National Hemophilia Foundation (2021) — Subcutaneous injection guidelines: needle length, angle, site preparation View Sourceet al. (2021)
- 10NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
- 11Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route View Source
- 12Pure Lab Peptides — PNC-27 (30 mg) product page (quality and batch documentation) View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Evidence is strictly preclinical (cell and/or animal models); it is a research compound, not a therapy, and has not been evaluated for human safety. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| PNC-27this | A synthetic peptide combining an HDM-2-binding domain with a membrane-penetrating sequence, studied for selective membrane disruption of cancer cells displaying surface HDM-2. | subcutaneous | Investigational / RUO |
| TB-500 | Upregulates actin, promotes cell migration, reduces inflammation, and stimulates wound healing and tissue repair. | subcutaneous, intramuscular | Investigational / RUO |
| BPC-157 | Promotes angiogenesis, accelerates wound healing, and protects organs. Interacts with growth hormone receptors and NO system. | subcutaneous, intramuscular | Investigational / RUO |
| GHK-Cu | Stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and acts as antioxidant and anti-inflammatory agent. | subcutaneous, topical | Investigational / RUO |
| KPV | A C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (Lys-Pro-Val) studied for anti-inflammatory activity, proposed to act through intracellular pathways (e.g., NF-kB modulation) without melanocortin pigmentary activity. | subcutaneous | Investigational / RUO |
| Prostamax | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro) derived from prostate peptide-complex research, studied for tissue-specific regulatory effects on prostate tissue. | intramuscular | Investigational / RUO |
| PT-141 | A cyclic heptapeptide melanocortin receptor agonist (MC3R/MC4R), an active metabolite of melanotan II, acting on central melanocortin pathways studied for modulation of sexual-response signaling. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
It is a synthetic ~32-amino-acid chimeric research peptide that joins the HDM-2 (MDM2)-binding region of the p53 protein to a cell-penetrating / membrane-residency 'leader' sequence. In the published preclinical literature it is studied as a tool for investigating selective membrane disruption of cancer cells in laboratory and animal models. It is a Research Use Only compound, not a medicine.
Research proposes that PNC-27 binds HDM-2 that is present in the plasma membrane of cancer cells, forming transmembrane pores associated with necrosis (membranolysis); some studies additionally report mitochondrial membrane localization and disruption. Normal cells, which the studies report do not display membrane HDM-2, were not affected in these models. These are proposed mechanisms in research systems, not established effects in people.
No. Based on PubMed and ClinicalTrials.gov, there are no registered human clinical trials. The evidence base is in vitro (cell lines), ex vivo (patient-derived cells handled in the laboratory), and animal (rodent) models. Findings in cells and animals do not establish what happens in humans.
There is a real multi-paper indexed literature (roughly 2001-2024), which is more than many research peptides have, so it should not be characterized as having no data. That said, most work comes from one affiliated research group, independent replication is limited, and all of it is preclinical - so the findings are best treated as preliminary. One independent group did report in vivo activity in leukemia models.
Reported values vary and are specific to laboratory and animal-model conditions (for example, micromolar concentrations in cell assays and model-specific regimens in mice). There is no established human dosing. For any protocol parameters, consult the original published methods (the protocol reference). This is not medical advice.
In the cited preclinical work, authors reported selectivity for cancer cells relative to the normal cells tested, and some animal studies reported limited off-target toxicity (for example, sparing of normal hematopoietic stem cells). These are observed effects in research models only; they do not predict outcomes in humans, and safety in people has not been established.
The indexed peer-reviewed literature on PNC-27 is in oncology and cell/membrane biology (selective cancer-cell membrane disruption), not wound healing or tissue regeneration. No indexed studies were found supporting a regenerative or 'healing' role. This appears to be a catalog categorization that does not match the published research base, and is flagged for reviewer attention.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.